Colinz Laboratories Limited (BOM:531210)

Market Cap	126.66M -8.6%
Revenue (ttm)	58.40M -12.9%
Net Income	4.94M +2.4%
EPS	1.96 +2.6%
Shares Out	2.52M
PE Ratio	25.65
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,537
Average Volume	14,226
Open	51.75
Previous Close	54.46
Day's Range	51.74 - 52.99
52-Week Range	36.11 - 88.70
Beta	0.07
RSI	39.85
Earnings Date	Jan 24, 2026

About Colinz Laboratories

Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin,...

• Industry: Pharmaceutical Preparations
• Founded: 1986
• Employees: 65
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531210

Financial Performance

In fiscal year 2025, Colinz Laboratories's revenue was 65.28 million, a decrease of -7.14% compared to the previous year's 70.30 million. Earnings were 4.97 million, an increase of 2.03%.